Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Executive VP, R&D | September 13, 2018 | September 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date September 13, 2018 · Filed September 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2028-09-13 | Direct | 700,000 |
Reported balance
After 2018-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-13 · Grant · Acquired 700,000 · Balance 700,000 F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. F2: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
F2: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2018 Filed Sep 14, 2018 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001144204-18-049515 · tv502880_4.xml · derivative · entry 1 Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2028-09-13 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | Exercise / conversionStock Options (Right to Buy) · Derivative | 122,162 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-16-124284 · v448888_4.xml · derivative · entry 3 Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 122,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents exercise of all stock underlying the derivative security. F3 · derivative.expiration_date: Represents exercise of all stock underlying the derivative security. F4 · balance_after: Does not include options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | Exercise / conversionCommon Stock | 122,162 | $0.00 | $122.16 |
DisclosureSEC source: 0001144204-16-124284 · v448888_4.xml · nonDerivative · entry 1 Shaaltiel Yoseph · CIK 0001385118 · Executive VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.